In this section

Implementation, not hesitation, for SGLT2 inhibition as foundational therapy for chronic kidney disease

Mark, P. B. and Sattar, N. (2022) Implementation, not hesitation, for SGLT2 inhibition as foundational therapy for chronic kidney disease. Lancet, 400(10365), pp. 1745-1747. (doi: 10.1016/S0140-6736(22)02164-X) (PMID:36351457)

[img] Text
285021.pdf - Accepted Version
Restricted to Repository staff only until 6 May 2023.
Available under License Creative Commons Attribution Non-commercial.
237kB

Abstract

No abstract available.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Mark, Professor Patrick and Sattar, Professor Naveed
Authors: Mark, P. B., and Sattar, N.
College/School:College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health
Journal Name:Lancet
Publisher:Lancet Publishing Group
ISSN:0140-6736
ISSN (Online):1474-547X
Published Online:06 November 2022
Copyright Holders:Copyright © 2022 Elsevier Ltd.
First Published:First published in Lancet 400(10365): 1745-1747
Publisher Policy:Reproduced in accordance with the publisher copyright policy

University Staff: Request a correction | Enlighten Editors: Update this record

Deposit and Record Details